FAST Congress

Biomarker Discovery Informatics - ADAPT Congress 2011

 

Day 1  |  Day 2 

Our Biomarker Discovery Informatics conference will bring together key players in the process of biomarker discovery – from early stage pharmaceutical research organizations, to late stage clinical trials organizations, as well as NIH and NIST – in an effort to address the informatics and organizational challenges inherent in the development of personalized and clinically relevant biomarkers. Challenges and solutions to identifying genomic and proteomic biomarkers will be discussed. Advanced data mining techniques for exhaustive analysis of biomarker data will be presented.

RECOMMENDED SHORT COURSE*

(SC3) Novel Cancer Biomarkers

(SC6) Integration and Analysis of Heterogeneous Translational Data 

*Separate registration required

 

THURSDAY, SEPTEMBER 8

 

12:30 pm Conference Registration

 

INTEGRATED AND RATIONAL APPROACH
FOR BIOMARKER DISCOVERY

1:30 Chairperson’s Opening Remarks

Michael Kalos, Ph.D., Director, Translational and Correlative Studies Laboratory, Stellar-Chance Laboratories; Adjunct Associate Professor, Department of Pathology and Laboratory Medicine, University of Pennsylvania

Keynote Presentation

1:40 Biostatistics in Biomarker Discovery: Is the Tail Wagging the Dog?

Francesco Marincola, Associate Director, Trans-NIH Center for Human Immunology, National Institutes of Health

Biomarker discovery is traditionally based on class comparison applying high stringency parameters. As the stringency is decreased to enhance the chance for discovery, specificity is gradually lost. In complex diseases where combinations of redundant, synergistic or antagonistic functions drive a given phenotype the problem is accentuated. In this presentation, we argue that biological principles driving bio-statistical inference may simplify the approach to biomarker discovery. An example will be provided derived from the analysis of genes relevant to the rejection of melanomas by immune cells.

2:10 Integrated Approach for Biomarker Discovery

Michael Kalos, Ph.D., Director, Translational and Correlative Studies Laboratory, Stellar-Chance Laboratories; Adjunct Associate Professor, Department of Pathology and Laboratory Medicine, University of Pennsylvania

Biomarkers drive in a fundamental manner translational and clinical research. Accordingly, appropriate development of biomarkers is fundamental for the ultimately successful development of new therapeutics. In this presentation we will discuss approaches to support the appropriate development of biomarkers, focusing on three elements: i. quality, ii. comprehensiveness, and iii. integratability of data sets.

2:40 Integrated Biomarker Discovery: An Architectural Blueprint

Janet Siebert, President, CytoAnalytics

To perform integrated biomarker discovery, we must combine data from a variety of sources and platforms. Possible data sources include demographics, longitudinal clinical records, HLA genotypes, and instrumentation platforms such as bead arrays, flow cytometers, and protein arrays. Often, a single tissue sample is divided into multiple aliquots and interrogated by multiple assays. In this presentation we describe an architectural blueprint for combining this heterogeneous data using proven methods and tools from data warehousing, and for applying platform-agnostic data analysis approaches to the integrated whole.

Sponsored by
NeoProteomics 
3:10 Network Biology: Approaches to Discover Robust Sub-Network Markers of Human Disease
Rod K. Nibbe, Ph.D.,  Senior Scientist, Director of Product Development, NeoProteomics, Inc.

Biology is fast undergoing a transformation to an information science. This is being driven by technological advances that have enabled us to measure global changes in the abundance or alteration of many biomolecules (e.g. DNA, mRNA, SNPs, PTMs, etc.), changes which provide clues to the molecular mechanisms underlying a variety of phenotypes. By using robust computational approaches to integrate this information, we identify quantitatively significant sub-networks useful to drive the discovery of well-validated drug targets and clinically relevant biomarkers.

3:40 Networking Refreshment Break in the Exhibit Hall with Poster Viewing

4:20 Designing Ontology Vocabulary for Comparing Cell Imaging and Other Experimental Data

John T. Elliott, Ph.D., Research Scientist, NIST/Biochemical Sciences Division

Identifying biomarkers that report cellular status can be facilitated by mining different biological databases and combining the results between comparable experiments. This task is often limited by the lack of common vocabulary terms that both describe experiments in detail and allow intersection between databases. We are exploring the use of a rules-based vocabulary development scheme to build use-case-dependent ontologies that optimize the possibility of data sharing between disparate biology databases. The vocabulary design concepts and an implementation in a cell image database will be presented.

4:50 Panel Discussion: Integrative Approaches in Biomarker Development

Moderator: Michael Kalos, Ph.D., Director, Translational and Correlative Studies Laboratory, Stellar-Chance Laboratories, University of Pennsylvania

Panelists:

Francesco Marincola, Associate Director, Trans-NIH Center for Human Immunology, National Institutes of Health

Michael Kalos, Ph.D., Director, Translational and Correlative Studies Laboratory, Stellar-Chance Laboratories, University of Pennsylvania

Janet Siebert, President, CytoAnalytics

John T. Elliott, Ph.D., Research Scientist, NIST/Biochemical Sciences Division

Don A. Baldwin, Ph.D., Director, Penn Molecular Profiling Facility, Adjunct Associate Professor of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine

5:50 Close of Day

6:30-9:00 Dinner Short Courses*

 

*Separate registration required

 

Day 1  |  Day 2